Lay Description

The purpose of this study is to see whether designing radiation to spare the vertebral bone marrow can limit the rates of lymphopenia during standard of care chemoradiation therapy and in the time to count recovery in the ensuing weeks. Secondary endpoints will examine whether this leads to improved disease control whether this is predictive of improved clinical outcomes such as rates of local recurrence (LR), metastasis free survival (MFS), overall survival (OS), and progression free survival (PFS) which will be followed prospectively up to 5 years.


  • Cancers and Other Neoplasms
  • Lungs, Breathing and Bronchial
  • Muscle, Bone and Cartilage
IRB Number
NCT Number
Open to Enrollment


Eligible Ages
18 and up
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • Patients with AJCC 8 T1-T4, N1-N3, M0 stage IIB, IIIA-IIIC NSCLC
  • Patients with oligometastatic disease stage IV, M1 disease, in which concurrent chemoradiotherapy to the thorax is planned with or without adjuvant immunotherapy
  • CBC/CMP within these limits
    • Eastern Cooperative Oncology Group (ECOG) 0-2
    • Absolute lymphocyte count>0.8K/μ
    • Hemoglobin>8 g/dL AST/ALT <2.5 times of ULN

Exclusion Criteria

  • History of thoracic irradiation
  • History of palliative radiation for the current malignancy under consideration
  • Patients not being treated with a curative approach to the chest
  • History of bone marrow disease and or leukemia
  • History of prior cytotoxic chemotherapy for a disease other than for the current malignancy
  • Polymetastatic disease, defined here as ≥3 or more extrathoracic metastases
  • Administration of concurrent immunotherapy during radiation therapy, either as part of another clinical trial or otherwise

Study Design

Arm Groups

Study Contact

Regulatory Point of Contact
Frances Crawford
(210) 450-5037

Regulatory Point of Contact
Sonia Creighton
(210) 450-1366

Regulatory Point of Contact
Myrna Montenegro
(210) 450-5954

Regulatory Point of Contact
Courtney Nichols
(210) 450-1794

Regulatory Point of Contact
Mailbox Ctrc Regulatory Affairs

Regulatory Point of Contact
Kathleen Rodriguez
(210) 450-1365

Regulatory Point of Contact
Pia Ashley Roperes
(210) 450-5626

Regulatory Point of Contact
Benjamin Schleif
(210) 450-1366

Regulatory Point of Contact
Morgan Seekatz
(210) 450-1133

Principal Investigator
Neil Newman